chlorisondamine has been researched along with Arterial Occlusive Diseases in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Altavilla, D; Bazzani, C; Bigiani, A; Bitto, A; De Meo, V; Giuliani, D; Guarini, S; Messineo, F; Minutoli, L; Mioni, C; Squadrito, F; Squadrito, G; Venuti, FS | 1 |
1 other study(ies) available for chlorisondamine and Arterial Occlusive Diseases
Article | Year |
---|---|
Activation of the cholinergic anti-inflammatory pathway reduces NF-kappab activation, blunts TNF-alpha production, and protects againts splanchic artery occlusion shock.
Topics: Animals; Anti-Inflammatory Agents; Arterial Occlusive Diseases; Chlorisondamine; Electric Stimulation; I-kappa B Proteins; Male; NF-kappa B; NF-KappaB Inhibitor alpha; Nicotinic Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Cholinergic; Shock; Splanchnic Circulation; Tumor Necrosis Factor-alpha; Vagus Nerve | 2006 |